@article{0a8a71d64b804d8784284f0105e2135b,
title = "Progress towards elimination goals for viral hepatitis",
abstract = "The global burden of viral hepatitis is substantial; in terms of mortality, hepatitis B virus and hepatitis C virus infections are on a par with HIV, malaria and tuberculosis, among the top four global infectious diseases. In 2016, the 194 Member States of the World Health Organization committed to eliminating viral hepatitis as a public health threat by 2030, with a particular focus on hepatitis B virus and hepatitis C virus infection. With only 10 years to go until the 2030 deadline is reached, and although much progress has been made towards elimination, there are still some important gaps in terms of policy and progress. In this Viewpoint, we asked a selection of scientists and clinicians working in the viral hepatitis field for their opinions on whether elimination of viral hepatitis by 2030 is feasible, what the key areas of progress are and what the focus for the next 10 years and beyond should be for viral hepatitis elimination.",
author = "Cox, {Andrea L.} and El-Sayed, {Manal H.} and Kao, {Jia Horng} and Lazarus, {Jeffrey V.} and Maud Lemoine and Lok, {Anna S.} and Fabien Zoulim",
note = "Funding Information: J.-H.K. thanks D.-S. Chen for his instructions and M. H. Lee, C. J. Liu, R. F. Pwu and H. I. Yang for providing their expert opinions. M.L. thanks the investigators, partners, funders and patients and their families of the PROLIFICA programme, and is also grateful to the European Commission, MRC UK, Gilead Sciences, Abbott, Echosens and Cepheid companies for their financial and technical support. J.V.L. is supported by a Spanish Ministry of Science, Innovation and Universities Miguel Servet grant (Instituto de Salud Carlos III/ESF, European Union [CP18/00074]) and further acknowledges support from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019-2023” Programme (CEX2018-000806-S), and from the Government of Catalonia through the CERCA Programme. F.Z. acknowledges J. French for critically reading the manuscript, and the International Coalition to eliminate HBV and ANRS for supporting research efforts to cure viral hepatitis. M.H.E.-S. acknowledges the Faculty of Medicine Ain Shams University Research Institute (MASRI) and the Egyptian National Committee for Control of Viral Hepatitis. Funding Information: Fabien Zoulim is Professor of Medicine at Lyon university, Head of the Hepatology Department at the Hospices Civils de Lyon, and Head of the viral Hepatitis research Laboratory at iNserM u1052, France. He is currently coordinating the aNrs “HBv cure” programme in France and the “iP-cure-B” project funded by the eu H2020 work programme. He co-founded the international Coalition to eliminate HBv (iCe-HBv). Publisher Copyright: {\textcopyright} 2020, Springer Nature Limited.",
year = "2020",
month = sep,
day = "1",
doi = "10.1038/s41575-020-0332-6",
language = "English (US)",
volume = "17",
pages = "533--542",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Publishing Group",
number = "9",
}